Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HOE140 Icatibant · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HOE140 Icatibant | DRUG | - |
Inclusion Criteria: * Male and female subjects with painful osteoarthritis of the knee. Exclusion Criteria: * Subjects presenting with diagnosis of OA \< 3 months and an OA grading \< K\&L grade II, with any condition with impact on on the target indication, any test-compound-related condition, a...
HOE140 Icatibant is an investigational small molecule being studied for the treatment of joint disease, specifically painful knee osteoarthritis. It is administered via intra-articular injection. The drug is currently in Phase 2 clinical development and is not yet approved for any use.
HOE140 Icatibant is a small molecule that targets the bradykinin B2 receptor. By blocking this receptor, it is intended to reduce pain and inflammation associated with joint disease, particularly knee osteoarthritis. This mechanism is being evaluated in clinical trials to assess its efficacy and safety.
HOE140 Icatibant is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the drug's safety and efficacy for the treatment of painful knee osteoarthritis.
HOE140 Icatibant is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for its potential to treat joint disease, specifically painful knee osteoarthritis, but it is still in the clinical trial stage.
HOE140 Icatibant has one completed Phase 2 clinical trial registered under NCT00303056. This study evaluated the efficacy and safety of intra-articular multiple doses of icatibant in patients with painful knee osteoarthritis. The trial enrolled 590 participants across the United States, Austria, Czechia, Germany, and Poland.
Yes, HOE140 Icatibant is the same as icatibant. HOE140 is a designation for the drug, which is also known by its generic name icatibant. In clinical trials, it is referred to as icatibant, and it is being studied for the treatment of painful knee osteoarthritis.